Mettler-toledo International

MTD · NYSE

$1,634.01+$8.28 (+0.51%)TodayMarket closed · Oct 20, 6:30 PM ET

Prev close $1,625.73

MTD analyst rating

HoldConsensus of 14 analysts over the last 12 months. 36% rate it a buy.

Strong buy0
Buy5
Hold8
Underperform0
Sell1

12-month price target · 16 analysts

Average $1,505.48 (−7.9% downside)

Low: $1,212.00
Now: $1,634.01
High: $1,707.30

Upgrades and downgrades

The latest rating actions, newest first

MTD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Morgan Stanley	Oct 13, 2026	Maintains	Equal-Weight	$1,450.00 → $1,575.00	56%
Barclays	Oct 7, 2026	Maintains	Overweight	$1,575.00 → $1,700.00	54%
UBS	Sep 9, 2026	Initiates	Buy → Neutral	$1,650.00 → $1,460.00	59%
Rothschild & Co	Sep 2, 2026	Initiates	Sell	$1,200.00	80%
RBC Capital	Sep 1, 2026	Initiates	Sector Perform	$1,515.00	59%
Morgan Stanley	Aug 4, 2026	Maintains	Equal-Weight	$1,275.00 → $1,450.00	56%
Evercore ISI Group	Aug 3, 2026	Maintains	Outperform	$1,350.00 → $1,500.00	52%
Wells Fargo	Aug 3, 2026	Maintains	Equal-Weight	$1,225.00 → $1,450.00	66%
Barclays	Aug 3, 2026	Maintains	Overweight	$1,300.00 → $1,575.00	54%
Stifel	Aug 3, 2026	Maintains	Buy	$1,400.00 → $1,600.00	65%

The case for and against

Updated Oct 15, 2026

Bull case

Mettler-Toledo Intl is attractive because it combines a premium precision-measurement franchise with leading positions, including more than 50% of the lab balances market, and a long record of pricing power, margin expansion, and consistent execution. Its diversified exposure across life sciences, industrial, and food retail, plus geographic breadth with roughly 37% of sales from the Americas, 27% from Europe, and 16% from China, supports resilience while service, bioprocessing, and China momentum offer visible growth levers. The outlook is further reinforced by free cash flow that can fund disciplined M&A, and by multi-year tailwinds from pharma reshoring and installed-base service penetration that should lift organic growth and earnings power.

Bear case

Mettler-Toledo Intl is viewed negatively because a meaningful share of its business is tied to structurally challenged end markets, especially packaged food manufacturing and grocery retail, where ~25% of sales face sustained capex pressure from private-label competition, e-commerce, and retail consolidation. Its China exposure at ~16% of sales adds cyclical risk, with further deterioration potentially pushing organic growth below 4% and eroding the premium multiple, while smaller businesses like Thornton and autochem are too limited to offset weakness. Although pricing and select life sciences areas provide some support, the broader mix still leaves earnings power exposed to soft industrial demand, slower R&D spending, and end-market fragility.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.